Abstract
Phase 1 Multiple Ascending Dose Study of Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Mitapivat (AG-348) in Subjects with Sickle Cell Disease
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have